Prognostic Value of Serum Heparanase Levels in Patients with Septic Shock
DOI:
https://doi.org/10.5281/zenodo.22644156Keywords:
heparanase, septic shock, endothelial glycocalyx, prognostic biomarker, heparan sulfateAbstract
Background: Septic shock carries persistently high mortality, and the microcirculatory failure that defines the syndrome is
inseparable from loss of endothelial glycocalyx integrity. Heparanase, the principal mammalian enzyme capable of cleaving
heparan sulfate, has emerged as both a mechanistic driver of glycocalyx degradation and a candidate circulating biomarker of
severity in sepsis. Objective: This narrative review synthesizes the preclinical and clinical literature on heparanase biology in sepsis
and evaluates the evidence for circulating heparanase as a prognostic biomarker in septic shock. Methods: We reviewed
mechanistic studies establishing heparanase's role in pulmonary, renal, and neurological injury during sepsis; clinical studies
measuring circulating heparanase level, procoagulant activity, or enzymatic activity in septic and septic shock cohorts and
relating these measures to severity and mortality; comparative evidence involving syndecan-1 and other glycocalyx biomarkers;
and intervention studies of pharmacological heparanase inhibition. Findings: Heparanase is activated by tumor necrosis
factor-alpha and drives glycocalyx degradation, neutrophil adhesion, and organ injury across the lung, kidney, gut, heart, and
brain in experimental sepsis. Clinical studies report associations between circulating heparanase-related measures and illness
severity, organ-specific injury, and mortality, although assay methodology and the direction of cross-sectional associations vary
across cohorts. Heparanase is mechanistically upstream of syndecan-1 shedding, and low molecular weight heparin, which inhibits
heparanase in addition to its anticoagulant activity, has improved gastrointestinal and cardiac outcomes in small clinical studies
of septic patients. Conclusions: Serum heparanase is a biologically well-justified and increasingly evidenced, but not yet fully
validated, prognostic biomarker in septic shock. Large, prospective, septic shock-specific cohorts using a standardized assay and
serial sampling, benchmarked against syndecan-1 and standard severity scores, are needed before heparanase measurement can
be recommended for routine prognostic use.
References
Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M (2020) Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. The Lancet, 395(10219):200-211, DOI:10.1016/S0140-6736(19)32989-7.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8):801-810, DOI:10.1001/jama.2016.0287.
Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M (2016) Developing a New Definition and Assessing New Clinical Criteria for Septic Shock. JAMA, 315(8):775-787, DOI:10.1001/jama.2016.0289.
Uchimido R, Schmidt EP, Shapiro NI (2019) The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Critical Care, 23(1):16, DOI:10.1186/s13054-018-2292-6.
Liao YE, Liu J, Arnold K (2023) Heparan sulfates and heparan sulfate binding proteins in sepsis. Frontiers in Molecular Biosciences, 10:1146685, DOI:10.3389/fmolb.2023.1146685.
Vlodavsky I, Kayal Y, Hilwi M, Soboh S, Sanderson RD, Ilan N (2023) Heparanase-a single protein with multiple enzymatic and nonenzymatic functions. Proteoglycan Research, 1(3):e6, DOI:10.1002/pgr2.6.
Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB, Tuder RM (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nature Medicine, 18(8):1217-1223, DOI:10.1038/nm.2843.
Lygizos MI, Yang Y, Altmann CJ, Okamura K, Andres-Hernando A, Perez MJ, Smith LP, Koyanagi DE, Gandjeva A, Bhargava R, Tuder RM, Faubel S, Schmidt EP (2013) Heparanase mediates renal dysfunction during early sepsis in mice. Physiological Reports, 1(6):e00153, DOI:10.1002/phy2.153.
Hippensteel JA, Anderson BJ, Orfila JE, McMurtry SA, Dietz RM, Su G, Ford JA, Oshima K, Yang Y, Zhang F, Han X, Yu Y, Liu J, Linhardt RJ, Meyer NJ, Herson PS, Schmidt EP (2019) Circulating heparan sulfate fragments mediate septic cognitive dysfunction. Journal of Clinical Investigation, 129(4):1779-1784, DOI:10.1172/jci124485.
Li JC, Wang LJ, Feng F, Chen TT, Shi WG, Liu LP (2023) Role of heparanase in sepsis-related acute kidney injury (Review). Experimental and Therapeutic Medicine, 26(2):379, DOI:10.3892/etm.2023.12078.
Chen D, Wang LJ, Li HL, Feng F, Li JC, Liu LP (2024) Progress of heparanase in septic cardiomyopathy: a review. Medicine, 103(33):e38901, DOI:10.1097/md.0000000000038901.
Matan M, King D, Peled E, Ackerman S, Bar-Lavi Y, Brenner B, Nadir Y (2018) Heparanase level and procoagulant activity are reduced in severe sepsis. European Journal of Haematology, 100(2):182-188, DOI:10.1111/ejh.12997.
Sallee CJ, Noa AS, Bhowmik M, Nobles AC, Wang Z, Liu J, Richter JR, Blalock JE, Patel RP, Gaggar A, Richter RP (2026) Age-related differences in circulating heparanase-1 activity in sepsis and correlation with systemic vascular endotheliopathy. Frontiers in Medicine, 13:1893157, DOI:10.3389/fmed.2026.1893157.
Chen TT, Lv JJ, Chen L, Li M, Liu LP (2023) Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis. World Journal of Gastroenterology, 29(35):5154-5165, DOI:10.3748/wjg.v29.i35.5154.
Daniyarova KR, Sarkulova ZN, Tamadon A, Tokshilykova AB, Sarkulov MN, Kalieva BM, Mussin NM, Safarzoda Sharoffidin R (2025) Glycocalyx and endothelial biomarkers as prognostic indicators in sepsis: a systematic review and meta-analysis. MicrobiologyOpen, 14(6):e70155, DOI:10.1002/mbo3.70155.
Chen D, Li H, Huang S, Huang Z, Sun Y, Liu L (2024) Heparanase inhibitor improves clinical study in patients with septic cardiomyopathy. Frontiers in Medicine, 11:1429109, DOI:10.3389/fmed.2024.1429109.
Abassi Z, Hamoud S, Hassan A, Khamaysi I, Nativ O, Heyman SN, Muhammad RS, Ilan N, Singh P, Hammond E, Zaza G, Lupo A, Onisto M, Bellin G, Masola V, Vlodavsky I, Gambaro G (2017) Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545. Oncotarget, 8(21):34191-34204, DOI:10.18632/oncotarget.16573.
Wang D, Wang K, Liu Q, Liu M, Zhang G, Feng K, Wang K, Ding X, Zhu H, Yang S, Liu Y, Li T, Gong P, Wang M, Wang PG, Jin H, Zhao W, Yu F (2024) A novel drug candidate for sepsis targeting heparanase by inhibiting cytokine storm. Advanced Science, 11(29):2403337, DOI:10.1002/advs.202403337.
